Article in Molecular genetics and metabolism reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 8 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 3 institutions in 2 countries.
Randall C MazzarinoKnoebel Institute for Healthy Aging, University of Denver, 2155 E. Wesley Avenue, Denver, CO 80210, USA.
Veronika BaresovaResearch Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Marie ZikánováResearch Unit for Rare Diseases, Department of Pediatrics and Adolescent Medicine, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic.
Nathan DuvalKnoebel Institute for Healthy Aging, University of Denver, 2155 E. Wesley Avenue, Denver, CO 80210, USA.
Terry G WilkinsonKnoebel Institute for Healthy Aging, University of Denver, 2155 E. Wesley Avenue, Denver, CO 80210, USA.
David PattersonKnoebel Institute for Healthy Aging, University of Denver, 2155 E. Wesley Avenue, Denver, CO 80210, USA.
Guido N VacanoKnoebel Institute for Healthy Aging, University of Denver, 2155 E. Wesley Avenue, Denver, CO 80210, USA.
Roosevelt Institute · USCharles University · CZGeneral University Hospital in Prague · CZ
Funding
University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
NCI NIH HHS P30 CA046934
6 · The paper itself
Abstract
In de novo purine biosynthesis (DNPS), 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase (EC 2.1.2.3)/inosine monophosphate cyclohydrolase (EC 3.5.4.10) (ATIC) catalyzes the last two reactions of the pathway: conversion of 5-aminoimidazole-4-carboxamide ribonucleotide [aka
Indexed as
5-aminoimidazole-4-carboxamide ribonucleoside, (AICAr)5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase, (ATIC)5-aminoimidazole-4-carboxamide ribonucleotide, (ZMP)5-formamido-4-imidazolecarboxamide ribonucleotide, (FAICAR)adenine phosphoribosyltransferase, (APRT)adenosine monophosphate, (AMP)adenosine triphosphate, (ATP)adenylosuccinate lyase, (ADSL)AICA-ribosiduriaAlzheimer's diseaseAMP-activated protein kinase, (AMPK)arachidonic acid, (AA)cyclooxygenase, (COX)cytochrome, P450 (CYP)cytosolic phospholipase A2, (cPLA2)de novo purine synthesis, (DNPS)Developmentdifferentially expressed gene, (DEG)false discovery rate, (FDR)fatty acid amide hydrolase, (FAAH)fetal calf macroserum, (FCM)fetal calf serum, (FCS)fragments per kilobase of exon per million reads mapped, (FPKM)gene ontology, (GO)guanosine monophosphate, (GMP)inosine monophosphate, (IMP)interferon, (INF)lipoxygenase, (LOX)mammalian Target of Rapamycin, (mTOR)minus adenine crATIC to minus adenine WT comparison, (MM)phospholipase, (PLA)phosphoribosylaminoimidazole carboxylase/phosphoribosylaminoimidazole succinocarboxamide synthetase, (PAICS)phosphoribosyl pyrophosphate, (PRPP)plus adenine crATIC to plus adenine WT comparison, (PP)Purine synthesisRNA-seqTuberous Sclerosis Complex 1 and 2, (TSC1 and TSC2)xanthine monophosphate, (XMP)
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The CRISPR-Cas9 crATIC HeLa transcriptome: Characterization of a novel cellular model of ATIC deficiency and ZMP accumulation. · full record | OpenQuestion